NasdaqGS:PHVSPharmaceuticals
Pharvaris (PHVS) Valuation Check After Conference Data Support For Deucrictibant Combination Regimen
Pharvaris (NasdaqGS:PHVS) is back in focus after new conference data supported the safety of combining its deucrictibant extended release tablet for prophylaxis with immediate release capsules for treating hereditary angioedema breakthrough attacks.
See our latest analysis for Pharvaris.
The latest conference data seems to have kept interest in Pharvaris alive, with a 1-year total shareholder return of 67.82% and a 3-year total shareholder return above 2x. At the same time, the 90-day share...